Industry Portals
Medical Device Industry News
Integer a velit nec risus malesuada imperdiet id et odio. Nunc sit amet mauris dapibus, feugiat diam eget, suscipit, nam gravida nulla eget turpis commodo.
Young & Partners 2024 Chemical Conference: Speakers Roundtable- What Does the Future Hold?
Joe Chang, Global Editor, ICIS Chemical Business Stephen Floyd, Managing Director, Young & Partners Dewey Johnson, SVP Chemical Market Analytics Lien-Hang T. Nguyen, Director of the Weatherhead East Asian Institute, Columbia University Charlie Vest, Associate Director, China Practice, Rhodium Group Peter Young, President and CEO, Young & Partners
Young & Partners 2024 Chemical Conference: Dewey Johnson: Global Energy & Chemical Markets – Emerging from the Trough
Dewey Johnson, SVP Dow Jones, Global Lead Chemical Market Analytics
Young & Partners 2024 Chemical Conference: Perspectives on Asia and the Middle East and the Impact on Chemicals
Dewey Johnson, SVP & Global Lead, Chemical Market Analytics Lien-Hang T. Nguyen, Director of the Weatherhead East Asian Institute, Columbia University Charlie Vest, Associate Director, China Practice, Rhodium Group Peter Young, President & CEO, Young & Partners
Young & Partners 2024 Chemical Conference: Joe Chang: The Current Challenges and the Future State of the Chemical Industry
Joe Chang, Global Editor, ICIS Chemical Business Peter Young, President and CEO, Young & Partners
Young & Partners Pharmaceutical Executive Summit 2024: The Impact of Artificial Intelligence on the Creation of Medicines (Pharmaceutical Executive)
Pharmaceutical Executive shares Fred Hassan's and Najat Khan's comments made at the 2024 Young & Partners Pharmaceutical Executive Summit. https://www.pharmexec.com/view/young-partners-pharmaceutical-executive-summit-2024-impact-artificial-intelligence-creation-medicines
Young & Partners 2024 Pharmaceutical Executive Summit: Speakers Roundtable- What Does the Future Hold
Michael Christel, Global Editor, MJH Life Sciences; Fred Hassan, Director, Warburg Pincus; Najat Khan, Chief R&D and Commercial Officer, Recursion; Doug Long, Vice President, Industry Relations, IQVIA; Peter Marks, M.D., Director, Center of Biologics Evaluation and Research, U.S. Food and Drug Administration; Dr. Stephen P. Spielberg, M.D. PhD, Senior Adviser, Young & Partners, former Deputy Commissioner for Medical Products and Tobacco, U.S. Food and Drug Administration; Sandy Zweifach, President and CBO, IMIDomics; Peter Young, CEO and President, Young & Partners
Young & Partners 2024 Pharmaceutical Executive Summit: Michael Christel and Sandy Zweifach- The Changing Roles and Relationships of Biotech and Pharma
Michael Christel, Global Editor, MJH Life Sciences; Sandy Zweifach, President and CBO, IMIDomics
Young & Partners 2024 Pharmaceutical Executive Summit: Fred Hassan and Najat Khan- The Impact of Artificial Intelligence on the Creation of Medicines
Fred Hassan, Director, Warburg Pincus; Najat Khan, Chief R&D and Commercial Officer, Recursion
Young & Partners 2024 Pharmaceutical Executive Summit: Doug Long: The Pharmaceutical Market: Trends, Issues and Outlook
Doug Long, Vice President, Industry Relations, IQVIA Holdings Inc.
Young & Partners 2024 Pharmaceutical Executive Summit: Peter Marks and Stephen Spielberg Fireside Chat: Brave New World- Where Are We Heading?
Dr. Peter Marks, Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration; Dr. Stephen P. Spielberg, MD PhD, Senior Adviser, Young & Partners
Young & Partners 2024 Pharmaceutical Executive Summit: Peter Marks Fireside Chat: Brave New World- Where Are We Heading?
Dr. Peter Marks, Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration
Young & Partners Pharmaceutical Executive Summit 2024: Brave New World – Where Are We Heading? (Pharmaceutical Executive)
Pharmaceutical Executive shares Peter Marks' comments made at the 2024 Young & Partners Pharmaceutical Executive Summit. https://www.pharmexec.com/view/young-partners-pharmaceutical-executive-summit-2024-brave-new-world-where-heading-
Industry Restructuring & Inorganic Growth Through an Era of Chronic Oversupply (World Chemical Forum Speech September 10, 2024)
Young & Partners shares their thoughts and analysis of the global oversupply and uncertainties that have impacted the chemical markets. The presentation addresses the era of chronic oversupply, strategic assessments, M&A market conditions, and Strategic and M&A alternatives.
Chemical Debt Financing Rebounds (ICIS Chemical Business September 6 – September 12, 2024)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have rebounded chemical debt financings and the outlook for 2024.
Chemical M&A Retreats Further (ICIS Chemical Business August 31 – September 5, 2024)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed chemical M&A and the outlook for 2024.
Chemical Financing Activity Mixed (ICIS Chemical Business May 31 – June 6, 2024)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed chemical financing and the outlook for 2024.
Chemical M&A Market Retreats (ICIS Chemical Business May 17 – May 23, 2024)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed M&A and the outlook for 2024.
Young & Partners Chemical Financing: Reflections on 2023 and Outlook (March 2024)
Proprietary data and analysis of chemical financing trends in 2023 and the current outlook.